Celldex Therapeutics (CLDX) FCF Margin (2010 - 2026)
Celldex Therapeutics' (CLDX) quarterly FCF Margin came in at 448260.0% in Q1 2026, down 44039856.0% year-on-year from N/an in Q1 2025, and down 731.56% quarter-over-quarter from 53905.79% in Q4 2025.
Celldex Therapeutics (CLDX) FCF Margin (2010 - 2026) Analysis & Trends
Celldex Therapeutics' FCF Margin history runs 17 years deep, the most recent figure standing at 448260.0% for Q1 2026.
- On a quarterly basis, FCF Margin fell 44039856.0% year-over-year to 448260.0% in Q1 2026; TTM through Mar 2026 was 26127.14%, a 2383382.0% decrease from a year earlier, with the FY2025 full-year figure at 13829.06%, down 1155418.0% from the prior year.
- FCF Margin declined to 448260.0% in Q1 2026 per CLDX's latest filing, from 53905.79% in the prior quarter.
- Across five years, FCF Margin topped out at 803.66% in Q4 2023 and bottomed at 448260.0% in Q1 2026.
- The 5-year median for FCF Margin is 6994.62% (2025), against an average of 37634.8%.
- Across the five-year window, FCF Margin surged 1840907 bps in 2025 and tumbled 44039856 bps in 2026, its largest moves.
- Year by year, FCF Margin stood at 1363.73% in 2022, then jumped by 41 bps to 803.66% in 2023, then slumped by 252 bps to 2828.26% in 2024, then slumped by 1806 bps to 53905.79% in 2025, then tumbled by 732 bps to 448260.0% in 2026.
- Per Business Quant, the three latest CLDX FCF Margin figures stand at 448260.0% (Q1 2026), 53905.79% (Q4 2025), and 6127.81% (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Celldex Therapeutics | 1.72 Mn | 1.72 Mn | -1.44 Mn | -448,260.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -448,260.00% |
| Dec 31, 2025 | -53,905.79% |
| Jun 30, 2025 | -6,127.81% |
| Mar 31, 2025 | -7,861.44% |
| Dec 31, 2024 | -2,828.26% |
| Sep 30, 2024 | -1,751.24% |
| Jun 30, 2024 | -1,184.99% |
| Mar 31, 2024 | -26,270.51% |
| Dec 31, 2023 | -803.66% |
| Sep 30, 2023 | -1,262.36% |
| Jun 30, 2023 | -10,300.75% |
| Mar 31, 2023 | -3,014.89% |
| Dec 31, 2022 | -1,363.73% |
| Sep 30, 2022 | -8,731.45% |
| Jun 30, 2022 | -14,059.51% |
| Mar 31, 2022 | -14,430.46% |
| Dec 31, 2021 | -4,454.19% |
| Sep 30, 2021 | -10,821.57% |
| Jun 30, 2021 | -346.93% |
| Mar 31, 2021 | -2,722.77% |